À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÁªºÏÐû²¼ £¬ÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö£¨FDA£©ÖÜΧºÍÖÐÊàÉñ¾ÏµÍ³Ò©Îï×ÉѯίԱ»á£¨PCNS£©È«Æ±Í¨¹ý £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾IIIÆÚClarity ADÁÙ´²ÊÔÑéÊý¾Ý֤ʵÁËLEQEMBI?£¨lecanemab-irmb£©100 mg/mL×¢ÉäÒºÓÃÓÚ¾²ÂöÖÎÁÆ°¢¶û´Äº£Ä¬²¡£¨AD£©µÄÁÙ´²»ñÒæ¡£´ËÍâ £¬Î¯Ô±»á³ÉԱȷÈÏÁËLEQEMBIµÄÕûÌå·çÏÕЧÒæÇé¿ö¡¢Êý¾ÝµÄÁÙ´²ÒâÒå £¬²¢ÌÖÂÛÁËÆäÔÚÌض¨ÑÇ×éÖеÄÓ¦Óà £¬°üÂÞÔØÖ¬ÂÑ°×E£¨ApoE£©¦Å4ͬÐÍ»¼Õß¡¢ÐèҪͬʱʹÓÿ¹ÄýѪ¼ÁÖÎÁƵĻ¼ÕßÒÔ¼°ÄÔµí·ÛÑùѪ¹Ü²¡»¼Õß¡£
¶ÀÁ¢×¨¼ÒС×éµÄÒ»Ö¾ö¶¨ÊÇ»ùÓÚÔö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇ루sBLA£© £¬ÆäÖаüÂÞÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄ´óÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚClarity ADÊÔÑéµÄÊý¾Ý¡£Clarity ADÊÔÑéµ½´ïÁËÆäÔ¤ÉèµÄÖ÷ÒªÖյ㠣¬±íÃ÷Óëο½å¼ÁÏà±È £¬18¸öÔÂÄÚÈÏÖªºÍ¹¦Ð§Ï½µµÄËٶȾßÓÐÏÔÖøͳ¼ÆѧÒâÒ壨27% £¬p=0.00005£©¡£¶ÔÓÚʹÓÃÆäËü¾ÑéÖ¤µÄÁ¿±í¼ì²éÈÏÖªºÍ¹¦Ð§±ä»¯µÄ¶àÖضÔÕÕ´ÎÒªÖյ㠣¬Ò²ÊӲ쵽¾ßÓÐÏÔÖøͳ¼ÆѧÒâÒåµÄÖÎÁÆЧ¹û¡£LEQEMBI×é×î³£¼ûµÄ²»Á¼Ê¼þ£¨>10%£©ÊÇÊäÒº·´Ó³£¨LEQEMBI£º26.4% £»Î¿½å¼Á£º7.4%£©¡¢ARIA-H£¨LEQEMBI£º17.3% £»Î¿½å¼Á£º9.0%£© £¬ARIA-E£¨LEQEMBI£º12.6% £»Î¿½å¼Á£º1.7%£© £¬Í·Í´£¨LEQEMBI£º11.1% £»Î¿½å¼Á£º8.1%£©ÒÔ¼°µøµ¹£¨LEQEMBl£º10.4% £»Î¿½å¼Á£º9.6%£©¡£ÊäÒº·´Ó³Ö÷ÒªÊÇÇá¶ÈÖÁÖжȣ¨1-2¼¶£º96%£© £¬²¢ÔÚµÚÒ»´ÎÓÃҩʱ·¢Éú£¨75%£©¡£Clarity ADÑо¿µÄ½á¹ûÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏÐû²¼ £¬²¢Í¬Ê±·¢±íÔÚͬÐÐÆÀÉóµÄҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£
LEQEMBIÊÇÒ»ÖÖÕë¶Ô¾Û¼¯¿ÉÈÜÐÔ(¡°ÔÏËά¡±)ºÍ²»ÈÜÐÔµí·ÛÑùÂѰצ£¨A¦Â£©ÐÎʽµÄÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ìå £¬FDAÔÚ¿ìËÙͨµÀÈ϶¨ÏÂÅú×¼ £¬²¢ÓÚ2023Äê1ÔÂ18ÈÕÔÚÃÀ¹úÉÏÊС£¿ìËÙͨµÀÏÂÅú×¼ÊÇ»ùÓÚIIÆÚÊý¾Ý £¬¸ÃÊý¾Ý±íÃ÷LEQEMBI¼õÉÙÁËA¦Â°ß¿éÔÚ´óÄÔÖеĻýÀÛ £¬ÕâÊÇADµÄÒ»¸ö¾ö¶¨ÐÔÌØÕ÷ £¬Æä¼ÌÐøÅú׼ȡ¾öÓÚÔÚÈ·ÈÏÐÔµÄClarity ADÊÔÑ飨Ñо¿301£©ÖÐÑéÖ¤LEQEMBµÄÁÙ´²»ñÒæ¡£ ×ÉѯίԱ»áÒ»ÖÂͬÒâ £¬Ñо¿301ÑéÖ¤ÁËÁÙ´²Òæ´¦¡£´¦·½Ò©Ê¹Ó÷ѷ¨°¸£¨PDUFA£©µÄ´«Í³Åú×¼Ðж¯ÈÕÆÚÊÇ2023Äê7ÔÂ6ÈÕ¡£
LecanemabµÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼ £¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹ㡣ÆäÖÐ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£
